Drug Profile

Research programme: bispecific antibodies - ABL Bio/I-MAB Biopharma

Alternative Names: ABL50X; Anti-cancer bispecific antibody therapeutics - I-MAB Biopharma; TJ-L14B

Latest Information Update: 28 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator I-MAB Biopharma
Developer ABL Bio; I-MAB Biopharma
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action CD137 antigen agonists; Immunomodulators; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Sep 2023 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
28 Sep 2023 No recent reports of development identified for preclinical development in Solid-tumours in South Korea (Parenteral)
31 Mar 2021 The US FDA approves an IND to initiate a phase I dose escalation study of TJ L14B in Solid tumours in USA, prior to March 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com